Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on DBV Technologies SA – American, boosting the price target to $48.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sam Slutsky’s rating is based on several notable factors that highlight the strong potential of DBV Technologies’ Viaskin Peanut treatment. The pivotal Phase 3 VITESSE trial produced significant results, with 46.6% of children aged 4-7 responding positively compared to only 14.8% on placebo. Importantly, the study exceeded FDA thresholds for treatment success, meeting the lower bound requirement for the confidence interval, and demonstrated excellent safety and tolerability, with a very low rate of treatment discontinuation. These findings boost confidence in the company’s regulatory strategy, as plans are underway for a Biologics License Application (BLA) submission in the first half of 2026, with a potential for priority review.
Slutsky also emphasized the substantial market opportunity for Viaskin Peanut, as it addresses an unmet need by providing a safe, effective, and convenient treatment for peanut allergies in children. The patch’s at-home administration, minimal risk of severe allergic reactions, and lack of lifestyle constraints make it particularly appealing to families. Additionally, the comprehensive market research, including input from key opinion leaders and allergy specialists, solidifies the long-term value of this therapy. Combining these factors with the extended operational runway expected from warrant funding further supports Slutsky’s optimistic Buy rating for DBV Technologies.
According to TipRanks, Slutsky is a top 100 analyst with an average return of 40.3% and a 50.92% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Palvella Therapeutics, Olema Pharmaceuticals, and Cogent Biosciences.
In another report released today, Citizens JMP also maintained a Buy rating on the stock with a $45.00 price target.